Axovia Therapeutics is dedicated to the research and development of novel AAV gene therapies that target key aspects of ciliopathies, addressing the devastating impact of the disease head-on for patients, their families and caregivers.
Axovia is currently developing therapies for patients with mutations in the BBS1 gene which manifests as Bardet Biedl Syndrome. Our initial goal is to halt the progression of BBS by targeting the most debilitating aspects of the neurological, metabolic and retinal dysfunctions.
Company Details
- Employees
- 9
- Address
- 78 Pall Mall, London,england Sw1y 5es,united Kingdom
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- https://axoviatherapeutics.com/
- HQ
- London, England
Axovia Therapeutics Questions
Axovia Therapeutics's website is https://axoviatherapeutics.com/
Axovia Therapeutics's LinkedIn profile is https://uk.linkedin.com/company/axoviatherapeutics
Axovia Therapeutics has
9 employees.
View email and phone details for 9
employees at Axovia Therapeutics.
Axovia Therapeutics's industry is
Biotechnology Research
Axovia Therapeutics's top competitors are
Medtherapy Biotech,
Genprex, Inc.,
Viralgen,
Rhythm Pharmaceuticals Inc.,
Vantage Biosciences,
Noga Therapeutics,
Alaya.bio,
Meiragtx,
Jaguar Gene Therapy,
Promatix Biosciences Ltd.
Axovia Therapeutics's categories are Biotechnology Research
